The Neuro-Oncology Program has been an Established Research Program since 2005. The Program is led by a basic scientist, C. Stiles(DFCI), and a clinician, R. Martuza(MGH), both of whom bring years of leadership experience to their respective roles. The central focus of the Neuro-Oncology Program has been high grade-glioma in adults. The Program has a clinical trials portfolio that offers a range of therapeutic modalities for glioma, including: radiation, tumor vaccines, oncolytic viruses and signal transduction inhibitors. There are also two signal transduction pathways identified as areas of priority: VEGF antagonists and PI3K antagonists. Pediatric neuro-oncology is a growing area of interest. Genetically simple tumors of children have historically shed light on more common, genetically complex adult tumors. One of the significant strengths of the Neuro-Oncology Program in this regard is the presence of a strong pediatric oncology program anchored at DFCI for outpatient care and CHB, a nationally recognized pediatric hospital, for inpatient services, creating a unified pediatric oncology facility that has spanned both institutions for decades. Over the next five years, a goal is to move recent genetic insights from the bench to the bedside in order to improve the standard of clinical care and enable genetically-informed clinical trials. The Program plans to develop CLIA-certified assays for all """"""""actionable"""""""" genetic lesions in high-grade glioma and to apply these assays to every tumor resected at DF/HCC hospitals. There are 93 members in the Program drawn from all seven DF/HCC member institutions. They represent 13 departments of HMS and one department of HSPH. Collectively, members receive over $22.6 million in cancer-relevant funding, of which $8.1 million was from NCI and $10 million was from other peer-reviewed sponsors. During the project period (2006 to 2010), members published 997 articles in peer-reviewed journals, of which 18% were intra-programmatic, 33% were inter-programmatic, and 21% were interinstitutional. At the time of the CCSG renewal in 2005, the Program received a merit score of """"""""excellent to very good"""""""".

Public Health Relevance

High-grade gliomas in adult patients are generally incurable. Collectively, these tumors are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between the ages of 15 and 34. The goal of the Neuro-Oncology Program is to improve the standard of care for patients with these tumors through genetically informed clinical trials (a.k.a. personalized medicine) conducted on a new generation of targeted therapeutics (a.k.a. smart drugs).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-48
Application #
8469408
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
48
Fiscal Year
2013
Total Cost
$85,563
Indirect Cost
$63,431
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609

Showing the most recent 10 out of 411 publications